Long-term effects of beta-blocker use on lung function in Japanese patients with chronic obstructive pulmonary disease
- PMID: 28435245
- PMCID: PMC5391992
- DOI: 10.2147/COPD.S133071
Long-term effects of beta-blocker use on lung function in Japanese patients with chronic obstructive pulmonary disease
Abstract
Background: Some recent studies have suggested that beta-blocker use in patients with chronic obstructive pulmonary disease (COPD) is associated with a reduction in the frequency of acute exacerbations. However, the long-term effects of beta-blocker use on lung function of COPD patients have hardly been evaluated.
Patients and methods: We retrospectively reviewed 31 Japanese COPD patients taking beta-blockers for >1 year and 72 patients not taking them. The association between beta-blocker use and the annual change in forced expiratory volume in 1 second (FEV1) was assessed.
Results: At baseline, patient demographic characteristics were as follows: 97 males (mean age 67.0±8.2 years); 32 current smokers; and Global Initiative for Chronic Obstructive Lung disease (GOLD) stages I: n=26, II: n=52, III: n=19, and IV: n=6. Patients taking beta-blockers exhibited a significantly lower forced vital capacity (FVC), FEV1, and %FVC, and a more advanced GOLD stage. The mean duration of beta-blocker administration was 2.8±1.7 years. There were no differences in the annual change in FEV1 between patients who did and did not use beta-blockers (-7.6±93.5 mL/year vs -4.7±118.9 mL/year, P=0.671). After controlling for relevant confounders in multivariate analyses, it was found that beta-blocker use was not significantly associated with the annual decline in FEV1 (β=-0.019; 95% confidence interval: -0.073 to 0.036; P=0.503).
Conclusion: Long-term beta-blocker use in Japanese COPD patients might not affect the FEV1, one of the most important parameters of lung function in COPD patients.
Keywords: beta-blocker; chronic obstructive pulmonary disease; forced expiratory volume in 1 second; long-term; lung function; spirometry.
Conflict of interest statement
Disclosure The authors have no conflicts of interest to report.
Figures
Similar articles
-
Beta-blocker Use in Moderate and Severe Chronic Obstructive Pulmonary Disease.Med Arch. 2019 Apr;73(2):72-75. doi: 10.5455/medarh.2019.73.72-75. Med Arch. 2019. PMID: 31391690 Free PMC article.
-
Impact of selective and nonselective beta-blockers on the risk of severe exacerbations in patients with COPD.Int J Chron Obstruct Pulmon Dis. 2017 Oct 11;12:2987-2996. doi: 10.2147/COPD.S145913. eCollection 2017. Int J Chron Obstruct Pulmon Dis. 2017. PMID: 29066880 Free PMC article.
-
Factors associated with inadequate diagnosis of COPD: On-Sint cohort analysis.Int J Chron Obstruct Pulmon Dis. 2015 May 18;10:961-7. doi: 10.2147/COPD.S79547. eCollection 2015. Int J Chron Obstruct Pulmon Dis. 2015. PMID: 26028969 Free PMC article.
-
β-Blockers and the Rate of Chronic Obstructive Pulmonary Disease Exacerbations.Ann Pharmacother. 2019 Dec;53(12):1249-1258. doi: 10.1177/1060028019862322. Epub 2019 Jul 4. Ann Pharmacother. 2019. PMID: 31271049 Review.
-
[Controversies and dilemmas on the use of beta-blockers in treatment of associated cardiovascular disease in patients with chronic obstructive pulmonary disease].Pneumologia. 2010 Jan-Mar;59(1):27-30. Pneumologia. 2010. PMID: 20432790 Review. Romanian.
Cited by
-
Beta-blocker therapy in patients with COPD: a systematic literature review and meta-analysis with multiple treatment comparison.Respir Res. 2021 Feb 23;22(1):64. doi: 10.1186/s12931-021-01661-8. Respir Res. 2021. PMID: 33622362 Free PMC article.
-
One Molecule, Many Faces: Repositioning Cardiovascular Agents for Advanced Wound Healing.Molecules. 2024 Jun 20;29(12):2938. doi: 10.3390/molecules29122938. Molecules. 2024. PMID: 38931002 Free PMC article. Review.
-
Reactive Oxygen Species and Antioxidative Defense in Chronic Obstructive Pulmonary Disease.Antioxidants (Basel). 2021 Sep 28;10(10):1537. doi: 10.3390/antiox10101537. Antioxidants (Basel). 2021. PMID: 34679673 Free PMC article. Review.
-
Effects of the Use of Beta-Blockers on Chronic Obstructive Pulmonary Disease Associated with Cardiovascular Comorbities: Systematic Review and Meta-analysis.Tuberc Respir Dis (Seoul). 2024 Jul;87(3):261-281. doi: 10.4046/trd.2024.0013. Epub 2024 Apr 4. Tuberc Respir Dis (Seoul). 2024. PMID: 38575301 Free PMC article.
-
Effect of Pingchuan Guben decoction on patients with chronic obstructive pulmonary disease: Results from a randomized comparative effectiveness research trial.Exp Ther Med. 2017 Oct;14(4):3915-3925. doi: 10.3892/etm.2017.5018. Epub 2017 Aug 24. Exp Ther Med. 2017. PMID: 29043001 Free PMC article.
References
-
- Vestbo J, Hurd SS, Agusti AG, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med. 2013;187:347–365. - PubMed
-
- Brusselle GG, Joos GF, Bracke KR. New insights into the immunology of chronic obstructive pulmonary disease. Lancet. 2011;378:1015–1026. - PubMed
-
- Feary JR, Rodrigues LC, Smith CJ, Hubbard RB, Gibson JE. Prevalence of major comorbidities in subjects with COPD and incidence of myocardial infarction and stroke: a comprehensive analysis using data from primary care. Thorax. 2010;65:956–962. - PubMed
-
- Lechat P, Packer M, Chalon S, Cucherat M, Arab T, Boissel JP. Clinical effects of beta-adrenergic blockade in chronic heart failure: a meta-analysis of double-blind, placebo-controlled, randomised trials. Circulation. 1998;98:1184–1191. - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical